Roquefort Therapeutics (LON:ROQ) Trading Down 10.5% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) fell 10.5% on Wednesday . The company traded as low as GBX 2.32 ($0.03) and last traded at GBX 2.33 ($0.03). 1,770,633 shares were traded during mid-day trading, a decline of 13% from the average session volume of 2,032,882 shares. The stock had previously closed at GBX 2.60 ($0.03).

Roquefort Therapeutics Price Performance

The stock has a market cap of £3.05 million, a PE ratio of -1.98 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The company’s 50 day moving average is GBX 3.76 and its 200-day moving average is GBX 3.91.

Insider Transactions at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West acquired 400,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,081.06). Insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.